Evidence map›Paper›PMID 19959680›Full record

ReviewCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2009

Surveillance methods for identifying, characterizing, and monitoring tobacco products: potential reduced exposure products as an example.

Richard J O'Connor, K Michael Cummings, Vaughan W Rees, Gregory N Connolly, Kaila J Norton, David Sweanor, Mark Parascandola, Dorothy K Hatsukami, Peter G Shields

Open access · bronzeAbstract readReview
In one paragraph

Review in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Measures for assessing subjective effects of potential reduced-exposure products.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2009
    Pooled it
  2. An Examination of the Variation in Estimates of E-Cigarette Prevalence among U.S. Adults.International journal of environmental research and public health · 2019
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Research priorities for FCTC Articles 20, 21, and 22: surveillance/evaluation and information exchange.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2013
    Review
  9. Tobacco industry strategies to minimize or mask cigarette smoke: opportunities for tobacco product regulation.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2013
    Article
  10. Tobacco and nicotine product testing.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2012
    Review
  11. Postmarketing surveillance for "modified-risk" tobacco products.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2012
    Review
  12. Research opportunities related to establishing standards for tobacco products under the Family Smoking Prevention and Tobacco Control Act.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2012
    Article
  13. Article
  14. A clinical laboratory model for evaluating the acute effects of electronic "cigarettes": nicotine delivery profile and cardiovascular and subjective effects.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2010
    Article
  15. Article
  16. Abuse liability assessment of tobacco products including potential reduced exposure products.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2009
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Richard J O'ConnorDepartment of Health Behavior, Roswell Park Cancer Institute, Buffalo, NY 14263, USA. Richard.O'Connor@roswellpark.org
K Michael Cummings
Vaughan W Rees
Gregory N Connolly
Kaila J Norton
David Sweanor
Mark Parascandola
Dorothy K Hatsukami
Peter G Shields
University of Minnesota · USUniversity of Ottawa · CAGeorgetown University · USGeorgetown University Medical Center · USRoswell Park Comprehensive Cancer Center · US

Funding

NCI NIH HHS N01 CN064402PHS HHS HHSN261200644002
6 · The paper itself

Abstract

Tobacco products are widely sold and marketed, yet integrated data systems for identifying, tracking, and characterizing products are lacking. Tobacco manufacturers recently have developed potential reduced exposure products (PREP) with implied or explicit health claims. Currently, a systematic approach for identifying, defining, and evaluating PREPs sold at the local, state, or national levels in the United States has not been developed. Identifying, characterizing, and monitoring new tobacco products could be greatly enhanced with a responsive surveillance system. This article critically reviews available surveillance data sources for identifying and tracking tobacco products, including PREPs, evaluating strengths and weaknesses of potential data sources in light of their reliability and validity. With the absence of regulations mandating disclosure of product-specific information, it is likely that public health officials will need to rely on a variety of imperfect data sources to help identify, characterize, and monitor tobacco products, including PREPs.

Indexed as

Environmental MonitoringPopulation SurveillanceSmoking CessationEpidemiological MonitoringHumansInhalation ExposureTobacco ProductsTobacco Use DisorderUnited States

Identifiers

PMID19959680
PMCPMC4637821
OpenAlexW2053416605

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.